Microbix Announces Annual and Special Meeting Voting Results
March 30 2023 - 7:00AM
Microbix Biosystems Inc. (TSX: MBX, OTCQB: MBXBF)( “Microbix®” or
the “Company”), a life sciences innovator, manufacturer, and
exporter, announces the voting results from the Annual and Special
Meeting of Shareholders of the Company (the
“
Meeting”) which was held on March 29, 2023.
At the Meeting, 48.77% of the issued and
outstanding shares were represented. Shareholders voted in favour
of all resolutions brought before the Meeting. Details of all
resolutions that were voted upon are set out in the Management
Information Circular (the “Circular”) dated
February 17, 2023. The Circular is available on the Company’s
website (www.microbix.com) and on SEDAR (www.sedar.com).
All of the board of directors nominees listed in
the Circular were re-elected as directors of Microbix. Results of
the vote were as follows:
Nominee |
Votes For |
% Votes For |
Withheld |
% Withheld |
Peter M. Blecher |
60,346,509 |
97.56% |
1,512,357 |
2.44% |
Mark A. Cochran |
60,208,504 |
97.33% |
1,650,362 |
2.67% |
Vaughn C. Embro-Pantalony |
61,267,509 |
99.04% |
591,357 |
0.96% |
Joseph D. Renner |
61,088,504 |
98.75% |
770,362 |
1.25% |
Martin Marino |
60,203,004 |
97.32% |
1,655,862 |
2.68% |
Cameron Groome |
60,461,092 |
97.74% |
1,397,774 |
2.26% |
Jennifer Stewart |
60,167,504 |
97.27% |
1,691,362 |
2.73% |
|
|
|
|
|
Shareholders also approved a resolution
re-appointing the Company’s auditors, Ernst & Young LLP, with
99.80% of the votes cast in favour.
The slides of management’s presentation at the
Meeting have been posted at www.microbix.com.
About Microbix
BiosystemsMicrobix creates proprietary biological products
for human health, with over 100 skilled employees and annualized
sales targeting C$ 2.0 million per month. It makes a wide range of
critical ingredients and devices for the global diagnostics
industry, notably antigens for immunoassays and its laboratory
quality assessment products (QAPs™) that support clinical lab
proficiency testing, enable assay development and validation, or
help ensure the quality of clinical diagnostic workflows. Its
antigens drive the antibody tests of approximately 100 diagnostics
makers, while QAPs are sold to clinical laboratory accreditation
organizations, diagnostics companies, and clinical laboratories.
Microbix QAPs are now available in over 30 countries, distributed
by 1WA (Oneworld Accuracy Inc.), Alpha-Tec Systems, Inc.,
Diagnostic International Distribution SpA., Labquality Oy, The
Medical Supply Company of Ireland, Neo-Science Equipment LLC,
R-Biopharm AG, SDT Molecular Pte Ltd, Seegene Canada Inc., and
Thomas Scientific LLC. Microbix is ISO 9001 and 13485 accredited,
U.S. FDA registered, Australian TGA registered, Health Canada
establishment licensed, and provides CE marked products.
Microbix also applies its biological expertise
and infrastructure to develop other proprietary products and
technologies, most notably viral transport medium (DxTM™) to
stabilize patient samples for lab-based molecular diagnostic
testing and Kinlytic® urokinase, a biologic thrombolytic drug used
to treat blood clots. Microbix is traded on the TSX and OTCQX, and
headquartered in Mississauga, Ontario, Canada.
Forward-Looking InformationThis
news release includes “forward-looking information,” as such term
is defined in applicable securities laws. Forward-looking
information includes, without limitation, all discussion regarding
Microbix products, Microbix’s business and business results, goals
or outlook, risks associated with financial results and stability,
development projects such as those referenced herein or in its
corporate presentation, regulatory compliance and approvals, sales
to foreign jurisdictions, engineering and construction, production
(including control over costs, quality, quantity and timeliness of
delivery), foreign currency and exchange rates, maintaining
adequate working capital or raising further capital on acceptable
terms or at all, and other similar statements concerning
anticipated future events, conditions or results that are not
historical facts. These statements reflect management’s current
estimates, beliefs, intentions and expectations; they are not
guarantees of future performance. The Company cautions that all
forward-looking information is inherently uncertain and that actual
performance may be affected by a number of material factors, many
of which are beyond the Company’s control. Accordingly, actual
future events, conditions and results may differ materially from
the estimates, beliefs, intentions and expectations expressed or
implied in the forward-looking information. All statements are made
as of the date of this news release and represent the Company’s
judgement as of the date of this new release, and the Company is
under no obligation to update or alter any forward-looking
information.
Please visit https://microbix.com or www.sedar.com
for recent Microbix news and filings.
For further information, please contact Microbix
at:
Cameron Groome, CEO(905) 361-8910 |
Jim Currie, CFO(905) 361-8910 |
Deborah Honig, Investor RelationsAdelaide Capital Markets(647)
203-8793 ir@microbix.com |
Copyright © 2023 Microbix Biosystems Inc.
Microbix®, DxTM™, Kinlytic®, and QAPs™ are trademarks of Microbix
Biosystems Inc.
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microbix Biosystems (TSX:MBX)
Historical Stock Chart
From Jul 2023 to Jul 2024